Mursla Bio

Mursla Bio publishes peer-reviewed study in the Journal of Extracellular Vesicles, validating its tissue-specific extracellular vesicle (TS-EV) platform for liquid biopsy.

This study validates our platform for a new class of liquid biopsy: the multiomic disease biology of living cells in a chosen tissue, read from blood, starting with the liver.

Our findings demonstrate the powerful advantages of isolating hepatocyte-derived EVs (h-EVs) over conventional bulk EV approaches:

🔬 A different proteome, not merely a deeper one: bulk EV isolates were dominated by abundant blood-secreted proteins, while h-EVs recovered the intracellular and membrane proteome of hepatocytes, and still identified 57% more proteins with higher reproducibility.

🔬 Disease signatures absent from bulk EVs: 86 liver disease-associated proteins in h-EVs versus 4 in bulk; the proteins unique to HCC h-EVs formed a coherent interaction network, while those unique to bulk EVs formed none.

🔬 Reduced miRNA diversity, richer disease association: h-EVs retained fewer microRNAs, yet only these mapped to HCC-relevant signalling pathways; bulk EV miRNAs reflected generalised inflammation.

These findings strengthen the scientific foundation of EvoLiver™, our FDA Breakthrough Device-designated blood test for liver cancer surveillance, and our precision medicine partnerships with pharmaceutical companies.

And the potential extends far beyond the liver. With further tissue-specific panels in development, our platform could unlock new opportunities in disease surveillance, molecular residual disease detection and precision medicine, from patient stratification to companion diagnostics.

🔗 Read the press release here: mursla.com/mursla-bio-pub…

🔗 Read the publication here: isevjournals.onlinelibrary.wiley.com/doi/10.1002/je…

#MurslaBio #LiquidBiopsy #ExtracellularVesicles #PrecisionMedicine #LiverCancer

Mursla Bio has been shortlisted for Best Emerging Biotech Company of the Year at the BioUK Awards 2026 🎉

BioUK (formerly @OBN_UK ) brings together one of the UK’s most established life sciences networks, connecting more than 530 organisations across biotech, pharma, investment and the wider ecosystem.

The award is sponsored by @thermofisher and judged by a jury of leaders from @EliLillyandCo, @CoEisai, @IpsenUSA, @RosFrankInst and other organisations across the life sciences sector. This national stage award follows our recent success at the Cambridge Independent Science & Technology Awards, where Mursla Bio was Highly Commended for MedTech Company of the Year.

This comes at an exciting time for Mursla Bio. Over the past year, we have continued to advance EvoLiver™, our blood based test for liver cancer surveillance in high risk patients, following FDA Breakthrough Device Designation. At the same time, we have been building new biopharma partnerships and expanding the application of our tissue specific extracellular vesicle (TS-EV) platform in precision medicine.

It reflects the dedication of our team as we continue to build the next phase of Mursla Bio.

Congratulations to all the finalists, and we look forward to the BioUK Awards in October.

#BioUKAwards #Biotech #LifeSciences #PrecisionMedicine #MurslaB

🎉 We are proud to announce that Mursla Bio is partnering with a leading global pharmaceutical company to advance its drug for metabolic liver disease.

For more information, check out our press release here: lnkd.in/eQEGCfRv

#PrecisionMedicine #MASH #Diagnostics #EVScience #BigPharma

✨ We are pleased that Mursla Bio’s core technology was recently featured on @RevvityInc (NYSE: RVTY) website, highlighting its unique precision diagnostic capabilities.

The article discusses how Mursla’s approach to isolating organ-specific extracellular vesicles (EVs) from plasma helps overcome a critical challenge in EV and microRNA research. Notably:
- In blood, almost all EVs originate from hematopoietic cells, drowning out signals from solid organs.
- Following the enrichment for hepatocyte-derived EVs by Mursla's technology, small RNA-seq libraries revealed microRNA species tightly linked to liver biology and liver cancer that were invisible in bulk EVs.

This is especially timely as microRNA biology was honored with the 2024 Nobel Prize in Medicine, underscoring its power as a key regulator of gene expression and as a relevant biomarker class.

Revvity concludes that:
- Organ-specific EVs deliver quality and biological resolution, unlike bulk EVs that only provide quantity.
- They enable signals from defined tissues to emerge by analogy to single-cell sequencing,
- This sets a new standard for reliable, multi-omic liquid biopsies with true biological interpretability.

This capability underpins Mursla Bio’s AI Precision Medicine Platform, which contributed to the development of EvoLiver™, our first product for liver cancer surveillance.

Check out the full post here: lnkd.in/eUS4C9_m

More details on our NEXPLOR technology can be found in our recent preprint: lnkd.in/dXk54iyS

🧬 Mursla Bio was recently featured in a new article by @statnews , as a leading company that’s supporting the shift to extracellular vesicles (EVs) for early cancer detection.

The article explains why many experts are looking beyond DNA-based blood tests. DNA is often present at low levels in early disease and breaks down easily, making detection difficult. EVs offer a compelling alternative. They are released by living cells and carry stable, information-rich cargo that reflects their tissue of origin, helping address critical gaps in test sensitivity and specificity.

Our first product, EvoLiver™, designed for the early detection of liver cancer, is based on our breakthrough platform that isolates organ specific EVs from blood. Our platform can be extended to support broader applications in AI enabled precision medicine across oncology, cardiometabolic diseases, and neurology.

Read the article here: statnews.com//2025/07/29/ea… [paywall]